The TREAT-NMD Advisory Committee for Therapeutics (TACT) held it’s Autumn meeting in Boston earlier this month. Four therapies for neuromuscular diseases were thoroughly reviewed by our expert panel who will provide invaluable feedback to help drive these therapies forward in the drug development process.
Each of the panels for the four reviews consisted of researchers, clinicians, regulatory experts and patients who will provide strategic guidance in the form of an advisory report to ensure these therapies are well-prepared to meet the challenges of drug development. This collaborative approach remains essential to advancing novel treatments for complex diseases.
Looking ahead, we are pleased to announce that the next TACT review meeting will take place in between 2nd – 4th May 2025 in Athens, and applications for advice from our panel for this review period are now open.
This is a fantastic opportunity for researchers and companies focused on rare neuromuscular diseases to gain invaluable feedback from an esteemed panel of international experts. TACT is dedicated to advancing therapeutic development and offers a comprehensive and confidential review process to help you optimise your trial design and development.
What TACT Can Assist With:
- Trial Design: Enhance your clinical trial strategies with expert insights, ensuring a robust approach.
- Drug Formulation: Refine your formulations to improve efficacy and safety.
- Bioavailability and Toxicology: Ensure a thorough evaluation of safety and effectiveness for your trials.
- Regulatory and Marketing Considerations: Navigate the regulatory landscape with confidence through tailored guidance.
- Recommendations: Receive critical go-no-go milestones to support informed decision-making.
If you have a therapeutic development programme that could benefit from TACT’s insights, we encourage you to apply by getting in touch with us at info@treat-nmd.com
Together, we can make significant strides in advancing therapies for those affected by rare neuromuscular diseases.
